

Volume control and bioimpedance analysis in peritoneal dialysis

Francisco Ferrer¹, Anabela Rodrigues²

¹ Nephrology Department, Centro Hospitalar de Coimbra. Coimbra, Portugal.

² Peritoneal Dialysis Unit, Nephrology and Renal Transplantation Department, Hospital Geral de Santo António. Oporto, Portugal.

Received for publication: 29/11/2010
Accepted in revised form: 21/12/2010

■ ABSTRACT

Peritoneal dialysis patients develop a wide variety of changes in body composition, mainly reflecting hydration, nutrition and body fat mass. Volume status is now of enormous importance in the outcomes of PD patients, but its assessment is notoriously difficult in clinical practice. Clinical evaluation and chest X-ray, although of major importance, are not sensitive, and the abnormalities are often revealed at a late stage. Serum natriuretic peptides, although useful in the diagnosis of heart failure in the general population, are influenced by the existence of renal and cardiac disease, and thus their isolated use in volume evaluation may be cumbersome. The new techniques of body composition monitoring, namely bioimpedance analysis, have shown promising results in the evaluation of both hydration and nutritional status. Although their use in single measurements is not precise, serial evaluations are useful in the determination of clinically relevant changes in body composition. The purpose of this article is to review the available tools for volume evaluation, focusing on bioimpedance analysis and its clinically relevant advantages.

Key-Words:

Bioimpedance analysis; fluid overload; peritoneal dialysis.

■ INTRODUCTION

Many landmark studies published in recent years (EAPOS¹ or ADEMEX²) have pointed out the importance of volume control in the achievement of better outcomes in peritoneal dialysis (PD), relative to solute clearance. The Evidence Based Practice Guidelines 2005 included a minimum target for net ultrafiltration in anuric patients of 1.0 L/day³.

The consequences of volume expansion (quite frequent in end-stage renal disease (ESRD), and thus in patients on PD programmes) are well known and adversely interfere in the prognosis of these patients. In addition to all the deleterious effects on the cardiovascular system (hypertension, left ventricular hypertrophy and lately congestive heart failure), some studies have shown a complex interaction between volume overload and inflammation⁴ or malnutrition. Inflammation itself has been recognised as a predictor of mortality in ESRD, mainly cardiovascular mortality⁵, and the association with malnutrition and atherosclerosis (MIA syndrome) could help to explain these complex relations. In PD patients, the relationship between extracellular volume (ECV) expansion and inflammation is bidirectional: the ECV expansion could be the origin of inflammation⁶, but an inflammatory process may trigger volume expansion due to an increased peritoneal permeability and secondary fluid retention.

In patients on PD, the evaluation of fluid status and the definition of euvolaemia are two major challenges for the nephrologist. Indeed, fluid status in these patients is influenced by many factors (gender, race, comorbidity – namely the cardiac function and inflammation) and not only by balance between input and output of water and salt. The “dry weight” (euvolaemia) concept is also difficult to define: fluid overload is associated with worse cardiovascular outcomes⁷, but its depletion is a threat to the preservation of residual renal function⁸.

The purpose of this work is to review the methods of assessment of volume status in PD patients, focusing on bioimpedance analysis (BIA) and its advantages compared to others.

■ FLUID STATUS EVALUATION

The monitoring of hydration and the diagnosis of fluid balance problems is crucial in the standard evaluation of PD patients. Prompt detection of fluid abnormalities is essential to implement therapeutic changes and to ameliorate outcomes. At the current status of PD development, many tools are at the disposal of the practitioner, some quite easy to use (physical examination, chest X-ray), while others need specialised equipment and training to be correctly performed (BIA).

Routine physical examination, although useful, is a quite imprecise picture of fluid status. When common symptoms/signals of fluid overload (dyspnoea, peripheral oedema, crackles on lung auscultation) appear, a large amount of fluid excess has been accumulated, and so the absence of these signs of congestion does not exclude fluid overload. Hypertension and consecutive increments in the prescription of antihypertensive drugs are sometimes the only features of overload. Weight measurement, another essential tool in PD management, can be cumbersome in the evaluation of fluid or nutritional status. Indeed, malnutrition is a common and serious complication in these patients, and thus a stable body weight may mask protein-calorie malnutrition due to a concomitant increase in extracellular fluid retention.

Chest X-ray is another simple tool to monitor hydration; in fluid overloaded patients, signs of pulmonary venous congestion (as well as an increase in cardiac diameter) can be seen. However, these changes occur at a late stage, and thus this approach is not practical for short-term monitoring.

The measurement of inferior vena cava diameter with ultrasound and its collapsibility with respiration reflect the hydration status in dialysis patients, but the clinical value of this finding is debated⁹.

■ BRAIN NATRIURETIC PEPTIDES (BNP)

Some recent studies have focused on the importance of natriuretic peptides in volume status evaluation. These particular peptides are secreted by the ventricular myocytes in response to stretching, cardiac disease (such as ischaemic) or hormonal stimulation (angiotensin II, catecholamines), and thus have a marked utility in the diagnosis/prognosis of acute and chronic heart failure. However, their interpretation can be cumbersome in the simultaneous presence of heart and renal failure (cardiorenal syndrome), because their excretion is exclusively glomerular¹⁰. In the presence of renal insufficiency, new cut-off levels are needed to diagnose heart failure. A recent study, including haemodialysis outpatients, found that N-terminal pro-brain type natriuretic peptide (NT-proBNP) was not associated with cardiac dysfunction as assessed by transthoracic echo but was dependent on factors associated with volume overload¹¹.

In PD, several studies have tried to use BNP monitoring in the diagnosis of the hydration status. The Lee *et al.* study found no association between BNP and extracellular water (evaluated with BIA)¹². Hiramatsu *et al.* found a relation between icodextrin use and the decrease in NT-proBNP levels, due to extracellular water contraction¹³.

Despite these conflicting results of BNP in hydration monitoring, two studies, one from Wang *et al.*¹⁴, and another from the ADEMEX group¹⁵, have shown that NT-proBNP levels are highly predictive of survival and cardiovascular mortality in PD.

■ BODY COMPOSITION MONITORING TECHNIQUES AND BIOIMPEDANCE ANALYSIS

Body composition monitoring techniques are probably the most promising tools for objective evaluation of fluid and nutritional status in PD patients. Among these methods, bioimpedance analysis (BIA) is the most extensively studied, with an intrinsic capacity to predict survival⁷.

To a better interpretation of the results of body composition monitoring technique (including BIA), it is useful to understand the principles of body composition analysis¹⁶. This theory divides the body into two major compartments: fat mass and fat free mass (lean tissue). Whereas fat is homogenous, fat free mass (FFM) is heterogeneous, with different components, including bone mineral content. The major component of FFM is water, and total body water (TBW) normally accounts for 73% of FFM, although this percentage can vary with disease states, mainly those with disturbed water homeostasis. The assessment of lean tissue with BIA reflects nutritional state and hydration¹⁷. However, to give clinical usefulness in PD patients, body composition monitor must evaluate hydration and nutrition separately. For this purpose, TBW must be further divided into extracellular (ECW) and intracellular water (ICW) and lean tissue into body cell mass (BCM) and ECW. ECW reflects hydration degree, whereas BCM is a more specific marker of nutrition and wasting virtually unaffected by the hydration state. Fat mass, the other big compartment of the organism, could be evaluated by direct (densitometry, magnetic resonance imaging, for instance) or indirect (BIA) methods. With this latter methodology, fat is estimated indirectly from FFM and derives as the remainder of body weight. However to be precise, these techniques are dependent on a normal hydration status, so that an abnormal hydration causes erroneous estimate of lean tissue¹⁸.

■ PRINCIPLES OF BIA

BIA is based on the measurement of body's impedance to passage of a small alternating electric current between two skin electrodes (at the hands and feet). This electric current freely passes through body water

(the major component of lean tissue), with fat acting as an electric insulator. The obtained impedance is inversely proportional to body water content¹⁹.

In the earlier times, BIA was performed with single frequency (50 kHz) and TBW was estimated by regression equations. This method was unable to evaluate nutrition and hydration separately. Nowadays commercially available analysers use bioimpedance spectroscopy, with which reactance and resistance are evaluated with multiple frequencies. In fact, impedance comprises a resistance and a reactance component (the latter resulting from the capacitance effect of cell membranes); the relationship between these components is determined by ECW and by ratio ECW/ICW. Mathematical models of the obtained data estimate the resistance at frequency zero (where all current passes freely through ECW) and at infinite frequencies (where current passes through TBW). By plotting the subject's readings on a graph, this technique gives precise information about TBW, ECW and ICW, and thus determines whether they fall on normal range, and if not, the direction of deviation from normality²⁰.

■ CLINICAL APPLICABILITY OF BIA

With single measurements of BIA, on a particular occasion it is difficult to determine whether the body composition is normal or clinically relevant changes exist. Normal body composition widely varies among healthy individuals, in accordance to ethnicity and to the population used as referential. Thus, it is possible for an individual to develop significant bodily changes in hydration and nutritional status before they fall outside the normal range. In renal patients, the problem of defining normality is greater, because of the changes in body composition induced by the disease itself²¹. However BIA has brought insight into the volume status issue in PD and haemodialysis (HD) patients. While 24% of a population still have clinically relevant volume overload (more prevalent in PD and pre-HD patients than a post-HD group), comparable volume status can be obtained in PD and HD patients¹⁷. Also similar volume status was achieved either by continuous ambulatory and automated PD²².

For the nephrologist, it is quite attractive and helpful to use single measurements of BIA to assess hydration and to define dry weight. Although ECW reflects hydration status, it widely varies among subjects of different sizes. In this situation, ECW volume must be normalised to the patient size through the calculation of the ECW/ICW or the ECW/TBW ratios²³. However even with normalisation, these ratios suffer significant variations, and are higher in the female gender and in the elderly. By plotting these ratios on graphs against age and gender and by comparing the curves with the 95% confidence intervals for the general population, it is possible to obtain a more correct vision of the patient's hydration status. As a normality range is wide, however, a normal extracellular volume might not correspond to the ideal hydration status or to the dry weight. Considering the high prevalence of cardiovascular disease in PD patients, some will need higher ECW to avoid hypotension, while others will need a lower one to control pulmonary congestion. Also, because the denominators in these ratios reflect BCM, an elevation could not only reflect hyperhydration, but also wasting. The clinician should be aware of these possibilities and so, high ECW/TBW or ECW/ICW ratios cannot be simply interpreted as hydration indexes. Some authors proposed the normalisation of ECW to height or body surface area to assess hydration, in order to overcome the limitations associated with ECW/ICW or ECW/TBW ratios^{23,24}.

Additionally, BIA is also a useful tool to depict the complex relations between malnutrition-inflammation-atherosclerosis and volume status²⁵: fluid overload is often correlated with inflammation markers. Hypoalbuminaemia was found to be an important predictor of tissue overhydration which was not associated with increased plasma volume²⁶. Noteworthy, the BIA derived ratio extracellular mass (ECM)/body cell mass (BCM) shown to an independent predictor of long-term survival in PD patients²⁷.

Single BIA measurements have limitations in the evaluation of body composition, and there is a disagreement with other techniques of body composition analysis²⁸. However, the great advantage of multifrequency BIA seems to lie in the detection of changes in body composition, with serial measurements²⁹. Trends of changes in BIA parameters reflect trends of change in body compartments. These trends could be useful to monitor the patient's progress in

response to treatment changes. In this setting, alterations in ICW and ECW independently reflect nutritional and hydration changes, respectively, even when the weight is stable. Despite BIA's inability to measure fat, in a patient where the weight is increasing, but ECW and ICW remain stable, the alterations are probably due to an increase in fat mass. Therefore routine BIA measurements could be a more informative tool in the evaluation of the hydration and the nutritional status in a single patient. However, the complexity and limitations of this technique necessitate careful integration of the results with other clinico-laboratory data.

CONCLUSION

In recent years, volume control has gained a huge importance in achieving better outcomes in PD. Although it is quite difficult to evaluate, the clinician has a wide variety of methods at his/her disposal. Some are quite simple and in routine use (physical examination, chest X-ray). Others, while promising and more sensitive, need more investigation to confirm the results outlined until now (BNP measurement, BIA). Among the latter, BIA is an acceptable technique for patients and readily performed in a clinical setting to detect changes in hydration and nutrition, despite the wide variation in normal values in healthy populations. With this methodology, single evaluations are not totally reliable and need cautiously interpretation. Serial measurements, however, may be useful to detect variations in nutrition or in hydration earlier (in addition to clinical assessment) and to implement therapeutic changes, ameliorating overall results.

Conflict of Interest statement. None declared.

References

- 1 Brown EA, Davies SJ, Rutherford P, et al. EAPOS Group. Survival of functionally anuric patients on automated peritoneal dialysis: the European APD Outcome Study. *J Am Soc Nephrol* 2003;14:2948-57
- 2 Paniagua R, Amato D, Vonesh E, et al. Mexican Nephrology Collaborative Study Group. Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. *J Am Soc Nephrol* 2002;13:1307-20
- 3 European Best Practice Guideline working group on Peritoneal Dialysis. European Best Practice Guidelines for Peritoneal Dialysis. *Nephrol Dial Transplant* 2005;20 (Suppl 9):ix1-ix37

4. Ávila-Díaz M, Ventura MJ, Valle D, *et al.* Inflammation and Extracellular Volume Expansion are Related to Sodium and Water Removal in Patients on Peritoneal Dialysis. *Perit Dialysis Int* 2006;26:574-580
5. Arici M, Walls J. End Stage Renal Disease, Atherosclerosis and Cardiovascular Mortality: is C-Reactive Protein the Missing Link? *Kidney Int* 2001;59:407-14
6. Vicente Martínez M, Martínez-Ramírez L, Muñoz R, *et al.* Inflammation in Patients on Peritoneal Dialysis is associated to increased extracellular fluid volume. *Arch Med Res* 2004;35:220-4
7. Chen W, Guo LJ, Wang T. Extracellular water/intracellular water is a strong predictor in incident peritoneal dialysis patients. *Blood Purif* 2007;25:260-6
8. Jansen MA, Hart AA, Korevaar JC, Dekker FW, Boeschoten EW, Krediet RT. Predictors of the rate of decline of residual renal function in incident dialysis patients. *Kidney Int* 2002;62:1046-53
9. Woodrow G. Methodology of assessment of fluid status and ultrafiltration problems. *Perit Dial Int* 2007;27(Suppl):S143-S147
10. Ronco C, Haapio M, House AA. Cardiorenal Syndrome. *J Am Coll Cardiol* 2008;52:1527-9
11. Booth J, Pinney J, Davenport A. N-terminal proBNP—marker of cardiac dysfunction, fluid overload, or malnutrition in hemodialysis patients? *Clin J Am Soc Nephrol* 2010;5:1036-40
12. Lee JA, Kim DH, Yoo SJ, Oh DJ, Yu SH, Kang ET. Association between serum N-terminal pro-brain natriuretic peptide concentration and left ventricular dysfunction and extracellular water in continuous ambulatory patients. *Perit Dial Int* 2006;26:360-5
13. Hiramatsu T, Furuta S, Kakuta H. Favourable changes in lipid metabolism and cardiovascular parameters after icodextrin use. *Adv Perit Dial* 2007;36:58-61
14. Wang AY, Lam CW, Yu CM, *et al.* N-terminal pro-brain natriuretic peptide: an independent risk predictor of cardiovascular congestion, mortality, and adverse cardiovascular outcomes in chronic peritoneal dialysis patients. *J Am Soc Nephrol* 2007;18:321-30
15. Paniagua R, Amato D, Mujais S, *et al.* Predictive Value of Brain Natriuretic Peptides in Patients on Peritoneal Dialysis: Results from the ADEMEX Trial. *Clin J Am Soc Nephrol* 2008;3:407-15
16. Ellis KJ. Human body composition: in vivo methods. *Physiol Rev* 2000;80:649-80
17. Woodrow G, Devine Y, Cullen M, Lindley E. Application of bioelectrical impedance to clinical assessment of body composition in peritoneal dialysis. *Perit Dial Int* 2007;27:496-502
18. Devolder I, Verleysen A, Vijt D, Vanholder R, Van Biesen W. Body composition, hydration, and related parameters in hemodialysis versus peritoneal dialysis patients. *Perit Dial Int* 2010;30:208-14
19. Woodrow G. Methodology of assessment of fluid status and ultrafiltration problems. *Perit Dial Int* 2007;27(Suppl 2):S143-S147
20. Lindley E, Devine Y, Hall L, *et al.* A ward-based procedure for assessment of fluid status in peritoneal dialysis patients using bioimpedance spectroscopy. *Perit Dial Int* 2005;25(Suppl 3):S46-S48
21. Chamney PW, Wabel P, Moissl UM, *et al.* A whole-body model to distinguish excess fluid from the hydration of major body tissues. *Am J Clin Nutr* 2007;85:80-9
22. Davenport A, Willicombe M. Comparison of fluid status in patients treated by different modalities of peritoneal dialysis using multi-frequency bioimpedance. *Int J Artif Organs* 2009;32:779-86
23. Woodrow G, Oldroyd B, Wright A, Coward WA, Truscott JG. The effects of normalization of ECW volume as a marker of hydration in peritoneal dialysis patients and controls. *Perit Dial Int* 2005;25(Suppl 3):S49-S51
24. Koh KH, Wong HS, Go KW, Morad Z. Normalized Bioimpedance Indices Are Better Predictors of Outcome in Peritoneal Dialysis Patients. *Perit Dial Int* 2010 Jun 30. [Epub ahead of print]
25. Demirci MS, Demirci C, Ozdogan O, *et al.* Relations between malnutrition-inflammation-atherosclerosis and volume status. The usefulness of bioimpedance analysis in peritoneal dialysis patients. *Nephrol Dial Transplant* 2010 Oct 4. [Epub ahead of print]
26. John B, Tan BK, Dainty S, Spanel P, Smith D, Davies SJ. Plasma volume, albumin, and fluid status in peritoneal dialysis patients. *Clin J Am Soc Nephrol* 2010;5:1463-70
27. Avram MM, Fein PA, Borawski C, Chattopadhyay J, Matza B. Extracellular mass/body cell mass ratio is an independent predictor of survival in peritoneal dialysis patients. *Kidney Int* 2010;(Suppl.)117:S37-S40
28. Konings CJ, Kooman JP, Schonck M, *et al.* Assessment of fluid status in peritoneal dialysis patients. *Perit Dial Int* 2002;22:683-92
29. Kraemer M, Rode C, Wizemann V. Detection limit of methods to assess fluid status changes in dialysis patients. *Kidney Int* 2006;69:1609-20

Correspondence to:

Dr Francisco Ferrer
Rua Flávio Rodrigues nº 53, 1º esq
3000-550 Coimbra, Portugal
Email: franciscodina@gmail.com